19205-72-2

Basic information

• Product Name: 6-BROMO-3,4-DIHYDROQUINOLINE-2(1H)-THIONE
• Synonyms: 6-BROMO-3,4-DIHYDROQUINOLINE-2(1H)-THIONE
• CAS NO: 19205-72-2
• Molecular Formula: C₉H₈BrNS
• Molecular Weight: 242.14
• Mol File: 19205-72-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-BROMO-3,4-DIHYDROQUINOLINE-2(1H)-THIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-3,4-DIHYDROQUINOLINE-2(1H)-THIONE(19205-72-2)
• EPA Substance Registry System: 6-BROMO-3,4-DIHYDROQUINOLINE-2(1H)-THIONE(19205-72-2)

Safety Data

• Hazardous Substances Data: 19205-72-2(Hazardous Substances Data)

Upstream product

• 3279-90-1 6-bromo-3,4-dihydro-1H-quinolin-2-one 
• 553-03-7 3,4-dihydro-2(1H)-quinolone 
• 62-53-3 aniline 
• 3460-04-6 3-chloro-N-phenylpropionamide 

Relevant articles and documents

Substituted indole compounds, as well as using method and application thereof

The invention relates to substituted indole compounds, a using method and application of the substituted indole compounds, as well as a medicine composition including the compounds and application thereof. The compounds or medicine composition can be used for inhibiting reuptake of 5-hydroxytryptamine. The invention further relates to a method for preparing the compounds and the medicine composition, as well as application of the compounds and medicine composition in treatment of central nervous system dysfunction.

Triazole derivative having HSP90 (Heat Shock Protein) inhibiting activity, as well as preparation method and application of triazole derivative

The invention discloses a triazole derivative having an HSP90 (Heat Shock Protein) inhibiting activity, as well as a preparation method and an application of the triazole derivative. Specifically, the invention relates to the triazole derivative having a structure as shown in a formula (I), a stereisomer of the triazole derivative and a pharmaceutically acceptable salt, wherein the definition of each substituent group in the formula (I) and the definition in a description are the same. The compound with a novel structure has the HSP90 inhibiting activity, can be used to cure cancers, neurodegenerative disorders, inflammation diseases, autoimmune diseases, ischemic brain injuries and the like, and has a broad application prospect.

ALDOSTERONE SYNTHASE INHIBITORS

This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.

Synthesis, biological activity, and three-dimensional quantitative structure-activity relationship model for a series of benzo[c]quinolizin-3-ones, nonsteroidal inhibitors of human steroid 5α-reductase 1

New 5α-reductase 1 (5αR-1) inhibitors were designed to complete a consistent set of analogues suitable for a 3D QSAR study. These compounds were synthesized by a modification of the aza-Robinson annulation, further functionalized by Pd-catalyzed cross-coupling processes, and were tested with human 5αR-1 expressed in Chinese hamster ovary 1827 cells. It turned out that the potency of the resulting inhibitors was strongly dependent on the type of substitution at the 8 position, with the 1C50 values ranging from 8.1 to 1050 nM. The construction of this homogeneous set of molecules allowed a 3D QSAR study. In particular, comparative molecular field analysis (CoMFA) was used to correlate the potency of the inhibitors with their physicochemical features. Highly accurate evaluations of the atomic point charges were carried out by means of quantum chemical calculations at the DFT/B3LYP level of theory followed by the RESP fitting procedure. It turned out that increasing the reliability of electrostatic parameters greatly affected the statistical results of the QSAR analysis. The 3D QSAR model proposed could be very useful in the further development of 5αR-1 inhibitors, which are suitable candidates to be evaluated as drugs in the treatment of 5αR-1 related diseases such as acne and alopecia in men and hirsutism in women.